Windtree to Present at H.C. Wainwright 22nd Annual Global Investment Conference

WARRINGTON, Pa., Sept. 8, 2020 -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Frasier, president and chief executive officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference, being held virtually from September 14-16, 2020. The presentation is scheduled for Monday, September 14, 2020 at 5:00 p.m. EDT.

A live audio webcast will be available via the events page of the Windtree website at A replay of the presentation will be archived on the Windtree website for 30 days for those unable to listen live.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree is also developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, as well as evaluating other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions such as preventing lung injury. Also in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

For further information:
Contact Information: Monique Kosse, LifeSci Advisors, 212.915.3820 or;

Media contact: Darren Opland, Ph.D., LifeSci Communications, 646.627.8387 or

SOURCE Windtree Therapeutics, Inc.

Related Posts

Subscribe Our Newsletter